BRCA2 and cancer: In contrast, the majority of both BRCA2 mutation carriers and their matched wild‐type patients developed ER+ breast cancers and had overall similar breast cancer characteristics, except that BRCA2 mutation carriers more often developed higher grade cancers (P = .01).